Harrow (HROW) Current Deferred Tax Assets (2013 - 2014)
Harrow (HROW) posted Current Deferred Tax Assets of $30000.0 for Q4 2014, down 25.0% on a QoQ basis from $40000.0 in Q4 2013, and down 25.0% year-over-year from $40000.0 in Q4 2013.
Powered by 
Analysis
Harrow (HROW) Current Deferred Tax Assets (2013 - 2014) Analysis & Trends
Harrow has reported Current Deferred Tax Assets for 2 years, with the latest figure at $30000.0 in Q4 2014.
- On a quarterly basis, Current Deferred Tax Assets fell 25.0% year-over-year to $30000.0 in Q4 2014; TTM through Dec 2014 was $30000.0, a 25.0% decrease from a year earlier, with the FY2014 full-year figure at $30000.0, down 25.0% from the prior year.
- Current Deferred Tax Assets was $30000.0 for Q4 2014 at Harrow, down from $40000.0 in the prior quarter.
- The five-year high for Current Deferred Tax Assets was $40000.0 in Q4 2013, with the low at $30000.0 in Q4 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn |
| 10 | Harrow | 1.42 Bn | 1.33 Bn | 50.36 Mn |